FR24C1005I1 - ANTITUMORAL AGENT AND PROMOTER OF THE ANTITUMORAL EFFECT - Google Patents

ANTITUMORAL AGENT AND PROMOTER OF THE ANTITUMORAL EFFECT

Info

Publication number
FR24C1005I1
FR24C1005I1 FR24C1005C FR24C1005C FR24C1005I1 FR 24C1005 I1 FR24C1005 I1 FR 24C1005I1 FR 24C1005 C FR24C1005 C FR 24C1005C FR 24C1005 C FR24C1005 C FR 24C1005C FR 24C1005 I1 FR24C1005 I1 FR 24C1005I1
Authority
FR
France
Prior art keywords
antitumoral
promoter
effect
agent
antitumoral agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1005C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52628493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR24C1005(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of FR24C1005I1 publication Critical patent/FR24C1005I1/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Endocrinology (AREA)
FR24C1005C 2013-09-06 2024-01-24 ANTITUMORAL AGENT AND PROMOTER OF THE ANTITUMORAL EFFECT Active FR24C1005I1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013184684 2013-09-06
PCT/JP2014/073436 WO2015034032A1 (en) 2013-09-06 2014-09-05 Antitumor agent and antitumor effect enhancer

Publications (1)

Publication Number Publication Date
FR24C1005I1 true FR24C1005I1 (en) 2024-04-19

Family

ID=52628493

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1005C Active FR24C1005I1 (en) 2013-09-06 2024-01-24 ANTITUMORAL AGENT AND PROMOTER OF THE ANTITUMORAL EFFECT

Country Status (23)

Country Link
US (1) US9943537B2 (en)
EP (2) EP3042669B1 (en)
JP (2) JP6425653B2 (en)
KR (1) KR101993963B1 (en)
AU (1) AU2014316030C1 (en)
CY (1) CY1126037T1 (en)
DK (1) DK3042669T3 (en)
ES (1) ES2946472T3 (en)
FI (2) FI3042669T3 (en)
FR (1) FR24C1005I1 (en)
HR (1) HRP20230523T1 (en)
HU (2) HUE062034T2 (en)
LT (1) LT3042669T (en)
NO (1) NO2024005I1 (en)
PL (1) PL3042669T3 (en)
PT (1) PT3042669T (en)
RS (1) RS64243B1 (en)
RU (1) RU2682161C2 (en)
SI (1) SI3042669T1 (en)
TW (1) TWI641385B (en)
UA (1) UA121538C2 (en)
WO (1) WO2015034032A1 (en)
ZA (1) ZA201602258B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3042669T3 (en) 2013-09-06 2023-06-26 Taiho Pharmaceutical Co., Ltd. Antitumor agent and antitumor effect enhancer
US11612653B2 (en) 2016-01-08 2023-03-28 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
EP3442534A1 (en) * 2016-04-13 2019-02-20 Boehringer Ingelheim International GmbH Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
CN111032092A (en) * 2017-06-30 2020-04-17 韩国科学技术院 Conjugates of VEGF-GRAB proteins and drugs and uses thereof
KR20220154986A (en) 2021-05-14 2022-11-22 윤상은 Portable Mask Strap Cutter
AR127893A1 (en) * 2021-12-10 2024-03-06 Servier Lab CANCER THERAPY TARGETTING EGFR
TW202339786A (en) 2022-01-21 2023-10-16 日商中外製藥股份有限公司 Medicine for treating or preventing cancer
WO2024177036A1 (en) * 2023-02-20 2024-08-29 大鵬薬品工業株式会社 Ftd-tpi combination preparation, pd-1 pathway antagonist, and combination use of vegf pathway antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203683T3 (en) 1995-03-29 2004-04-16 Taiho Pharmaceutical Company Limited URACILO DERIVATIVES, ANTITUMORAL EFFECT POTENTIALIZING AGENTS AND ANTITUMORAL AGENT THAT INCLUDES THESE DERIVATIVES.
US7312243B1 (en) * 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
RU2394581C2 (en) 2005-01-26 2010-07-20 Тайхо Фармасьютикал Ко., Лтд. ANTICANCER MEDICINE, CONTAINING α,α,α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
ES2702911T3 (en) 2013-03-27 2019-03-06 Taiho Pharmaceutical Co Ltd Antitumor agent that includes a low dose of hydrated irinotecan hydrochloride
RU2657604C2 (en) * 2013-03-27 2018-06-14 Тайхо Фармасьютикал Ко., Лтд. Antitumour agent including irinotecan hydrochloride hydrate
PL3042669T3 (en) 2013-09-06 2023-06-26 Taiho Pharmaceutical Co., Ltd. Antitumor agent and antitumor effect enhancer

Also Published As

Publication number Publication date
HUE062034T2 (en) 2023-09-28
KR101993963B1 (en) 2019-06-27
EP3042669A4 (en) 2017-04-12
UA121538C2 (en) 2020-06-25
HUS2400001I1 (en) 2024-02-28
RU2682161C2 (en) 2019-03-15
FIC20240002I1 (en) 2024-01-25
JP2018076369A (en) 2018-05-17
DK3042669T3 (en) 2023-06-12
JP6425653B2 (en) 2018-11-21
FI3042669T3 (en) 2023-05-25
JP6557744B2 (en) 2019-08-07
RU2016112421A (en) 2017-10-11
TWI641385B (en) 2018-11-21
AU2014316030C1 (en) 2024-08-15
PL3042669T3 (en) 2023-06-26
CY1126037T1 (en) 2023-11-15
US20160193241A1 (en) 2016-07-07
TW201536319A (en) 2015-10-01
RS64243B1 (en) 2023-06-30
LT3042669T (en) 2023-06-26
NO2024005I1 (en) 2024-01-25
AU2014316030B2 (en) 2019-02-28
US9943537B2 (en) 2018-04-17
KR20160050026A (en) 2016-05-10
EP4201424A1 (en) 2023-06-28
JPWO2015034032A1 (en) 2017-03-02
EP3042669B1 (en) 2023-03-08
AU2014316030A1 (en) 2016-04-28
WO2015034032A1 (en) 2015-03-12
PT3042669T (en) 2023-06-15
RU2016112421A3 (en) 2018-06-20
EP3042669A1 (en) 2016-07-13
ZA201602258B (en) 2017-09-27
HRP20230523T1 (en) 2023-08-04
ES2946472T3 (en) 2023-07-19
SI3042669T1 (en) 2023-07-31

Similar Documents

Publication Publication Date Title
FR24C1005I1 (en) ANTITUMORAL AGENT AND PROMOTER OF THE ANTITUMORAL EFFECT
HK1226301A1 (en) Modified therapeutic agents and compositions thereof
HK1225654A1 (en) Compositions and methods for the treatment of presbyopia
IL265876A (en) Compositions comprising 15-ohepa and methods of using the same
IL240221A0 (en) Benzomorphan analogs and the use thereof
ZA201500698B (en) Hydroxamate substituted azaindoline-cyanine dyes and bioconjugates of the same
EP2970184A4 (en) Compounds and uses thereof for the modulaton of hemoglobin
HK1217896A1 (en) Compositions and methods for the treatment of pervasive development disorders
FR3009208B1 (en) HEAD OF DISTRIBUTION AND APPLICATION
HK1218122A1 (en) Co rti statin analogues for the treatment of inflammatory and or immune diseases
IL240248A0 (en) Met-binding agents and uses thereof
EP3679909C0 (en) Eye mask for amelioration or prevention of dry eye and the like
HK1223551A1 (en) Novel n-3 immunoresolvents: structures and actions n-3
HK1220374A1 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
EP2970977A4 (en) Root-preferred promoter and methods of use
EP2964750A4 (en) Methods and compositions for the treatment and/or prevention of type 1 diabetes
EP2966991A4 (en) Root-preferred promoter and methods of use
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB201305297D0 (en) Novel agents and uses thereof
GB201520487D0 (en) New game 'Shiki'
IL242818B (en) Il-1beta-il-1ra chimera and methods of using the same
UA27219S (en) FORMATOR-VULCANIZER 75" AND 88"
GB201302646D0 (en) Therapeutic uses of flavin-containing monooxygenase 3
TH1401002410B (en) The absorbent body and the absorbent product comprising the absorbent body
TH1401001876B (en) Continuous body of the cuff and cuff